The real-life efficacy and safety of secukinumab therapy (150 and 300 mg) in patients with moderate-to-severe plaque psoriasis: A twelve week, single center, retrospective study

Creative Commons License

YILDIZHAN İ., Aygun M., KUNDAKCI N.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.55, sa.3, ss.113-118, 2021 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4274/turkderm.galenos.2021.70446
  • Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.113-118
  • Anahtar Kelimeler: Anti-IL-17A, secukinumab, psoriasis, efficacy, side effects, ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY, LONG-TERM SAFETY, DOUBLE-BLIND, ANKYLOSING-SPONDYLITIS, TRIAL, MULTICENTER, ARTHRITIS
  • Ankara Üniversitesi Adresli: Evet

Özet

Background and Design: secukinumab is an effective treatment option in moderate-to-severe plaque type psoriasis. However, there are a few real-life data studies comparing the efficacy of 150 mg and 300 mg dosages. The aim of this study was to evaluate the efficacy and safety of secukinumab at 150 mg and 300 mg in dinical practice in chronic plaque type psoriasis patients attending our center.